CEL-SCI (STU:LSR) Short Percentage of Float


STU:LSR CEL-SCI Corp STU:LSR
23 GF Score
Price €5.58
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:LSR vs TRAW, QNCX, CRIS: Short Percentage of Float Comparison

For the Biotechnology subindustry, CEL-SCI's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Short Percentage of Float falls into.


STU:LSR
23GF Score
CEL-SCI Corp STU:LSR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Business Description

Other Exchanges CVM:USALSR:Germany
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
23GF Score

Get the complete analysis for STU:LSR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price